Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.
about
Neurologic indications for therapeutic plasma exchange: an update.Neurologic indications for therapeutic plasma exchange: 2011 update.Neurologic indications for therapeutic plasma exchange: 2013 update.Autoantibodies associated with peripheral neuropathy.New concepts of Guillain-Barré syndrome.Mechanisms for the induction of autoimmunity by infectious agents.Central nervous system infection during immunosuppression.Early recognition of poor prognosis in Guillain-Barre syndromeGanglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseasesAutoimmune neuropathies.Guillain-Barré syndrome, greater Paris area.Guillain-Barré syndrome in childhood.Weakness and the inability to ambulate in a 14-month-old female: a case report and concise review of guillain-barre syndrome.Ganglioside mimicry and peripheral nerve disease.Epidemiology of Guillain-Barré Syndrome in Aruba.Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy.A young patient with multisystem complications after cytomegalovirus infection.Infectious and noninfectious triggers in Guillain-Barré syndrome.Guillain-barré syndrome associated with acute onset bilateral facial nerve palsies. A case report and literature review.Pathophysiology and diagnosis of Guillain-Barré syndrome - challenges and needs.Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barré syndrome.Guillain-Barré syndrome in pregnancy: A case report.Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups.Electrophysiology to predict mechanical ventilation in Guillain-Barré syndrome.Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria.Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.Guillain-Barré Syndrome: A Variant Consisting of Facial Diplegia and Paresthesia with Left Facial Hemiplegia Associated with Antibodies to Galactocerebroside and Phosphatidic Acid.Role of gancyclovir and HAART administration in the treatment of a rare complication of HIV disease: cytomegalovirus-associated Guillain-Barré syndrome.A Guillain-Barré syndrome variant with prominent facial diplegia.Cytomegalovirus-associated periodontitis and Guillain-Barré syndrome.Investigation of the Role of Campylobacter Infection in Suspected Acute Polyradiculoneuritis in Dogs.Asymptomatic dengue infection may trigger Guillain-Barré syndrome.Clinical Heterogeneity of Anti-GM2-Ganglioside-Antibody Syndrome.
P2860
Q30454297-8C3A6C85-2883-4D28-981E-F63625419A34Q30455391-09656750-A478-4432-892C-0B55C9ACBA7CQ30458271-39D124E6-6438-405E-88A8-D0C8F73AA23AQ33682810-0C5D1164-6CE2-49F6-948D-A7B14D0DD875Q33886911-80820683-BCC5-420F-8BBD-3C1028D8D635Q34402318-D684EEEF-B2DA-45D5-BD2B-A1FB3DB4607FQ34469041-FE3E39C3-60A3-4915-97CF-6A119482C44CQ34686090-1281822C-3E65-41E2-AD9E-3F75F8A391F5Q35220367-1EF83AFF-6C5C-449F-AA78-A7A875700742Q35677692-F3B660BA-1A13-40F9-930D-7DAACCF127B4Q36026122-9714B7D7-8A38-4881-915E-FC3C4944204CQ36161577-F03811A2-DA8C-4D60-95FC-A643EAB2DE35Q36610437-66A6BB01-E368-4C03-A81B-5346504995C2Q36764831-45D14DCF-AAB7-4AF9-A15B-FA53C92A1E76Q36958561-E13B276C-1744-48F7-9BD8-9A3D6172AF59Q37329516-FEAF290A-AD00-42A2-901E-DF1BF5B45D31Q37625983-4881E9B6-628D-4E08-9C92-78A537BFCF86Q37700839-245B4529-29DE-4765-8289-56516B9BD7E3Q38125242-B81BEE66-FF9E-4A8F-9A8F-1D12933C2A2EQ38136814-0FABBD51-7317-4D97-8317-582059B0B9D8Q38204498-1E661987-40D3-434D-BA28-F75AC98BB6B7Q38914130-B19C55F8-4CAF-4D1F-8E6E-9562C673D8C1Q40239892-5E0492A9-B32F-4E3D-A5BE-F94D1DC5BCBBQ40603742-7DCE11A8-4F76-4A67-8F20-218583711270Q40609919-1BFF9D89-6A84-48D5-9883-58F599EC50E1Q40843367-489760A7-FB20-4BF3-BBF6-622CF0A995EFQ40862168-29D3DF56-B2C6-4959-A952-87E17A5F710DQ41838846-30E5708B-D9F3-44FD-A0CB-9F77EF9572A8Q42269427-0835B94F-E8C9-4955-B51B-836E2C88203EQ43836008-525A8E33-E8BD-409F-85CA-714FE77D9203Q45360740-763AC1C8-8D1D-4D4F-8DF1-863833BEF8BFQ46019916-1A88E675-929C-467A-BCDC-141D1B06EE6DQ48197643-FA06AA94-D119-4D7C-967D-2E8EA9D99DA3Q51807078-0BCA0BB0-FAD0-4DF5-8005-A928B3113D53Q55519293-8E14A2B3-BCF2-4EA0-BA16-22FAF5CCBC8A
P2860
Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@ast
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@en
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@nl
type
label
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@ast
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@en
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@nl
prefLabel
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@ast
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@en
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@nl
P2093
P921
P356
P1433
P1476
Cytomegalovirus infection and ...... ch Guillain-Barré Study Group.
@en
P2093
Meulstee J
Rothbarth PP
Schmitz PI
van Doorn PA
P304
P356
10.1212/WNL.47.3.668
P407
P577
1996-09-01T00:00:00Z